Skip to main content
Fig. 8 | Molecular Medicine

Fig. 8

From: Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes

Fig. 8

The scheme of fluvoxamine attenuates autoimmune progression in T1D setting. Fluvoxamine treatment inhibits glycolysis via restraining PI3K/AKT signaling. This metabolic change results in impaired differentiation and function of Th1 and Th17 cells. Consequently, administration of fluvoxamine delays diabetes onset and prevents autoimmune progression in T1D setting

Back to article page

Molecular Medicine

ISSN: 1528-3658